SCHEMBL7433528

SCHEMBL7433528

COC(=O)CCNCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.58
CA12 O43570 5/20 0.48
CA14 Q9ULX7 5/20 0.48
LTA4H P09960 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
LMNA P02545 3/20 0.39
ALDH1A1 P00352 2/20 0.39
CA7 P43166 3/20 0.39
CA9 Q16790 3/20 0.39
KDM4E B2RXH2 1/20 0.39
RECQL P46063 1/20 0.39
CA2 P00918 1/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11193382 0.88 TSHR (0.60) TSHRCA12CA14LTA4HKMT2A
SCHEMBL17817739 0.86 TSHR (0.52) TSHRCA12CA14KMT2AMEN1
SCHEMBL10667342 0.86 TSHR (0.57) TSHRCA12CA14LTA4HKMT2A
Hydrochloric Acid SCHEMBL15654082 0.84 TSHR (0.55) TSHRCA12CA14LTA4HKMT2A
SCHEMBL72889 0.83 TSHR (0.67) TSHRCA12CA14LTA4HKMT2A
SCHEMBL13969418 0.82 TSHR (0.52) TSHRCA12CA14LTA4HKMT2A
SCHEMBL7432168 0.82 EPHX2 (0.54) TSHRLMNAALDH1A1HSD17B10
SCHEMBL10056635 0.81
SCHEMBL7429768 0.81 GAA (0.48) LTA4HKMT2AEGLN1ALDH1A1MAPT
SCHEMBL12847508 0.80 TSHR (0.63) TSHRCA12CA14LTA4HKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0384636-A1 Pharmaceutically active compounds FISONS plc (GB) 1990-08-29 EP claimed
US-20230124955-A1 AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-04-20 US disclosed
US-20200330501-A1 AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-10-22 US disclosed
US-10745692-B2 Production method for charged non-protein amino acid-containing peptide THE UNIVERSITY OF TOKYO (JP) 2020-08-18 US disclosed
US-10682374-B2 Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof MASSACHUSETTS INTSTITUTE OF TECHNOLOGY (US) 2020-06-16 US disclosed
US-10351593-B2 Derivatives of dolastatin 10 and uses thereof NEWBIO THERAPEUTICS, INC. (CN) 2019-07-16 US disclosed
US-20190076462-A1 AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-03-14 US disclosed
US-20180141973-A1 Derivatives of Dolastatin 10 and Uses Thereof NEWBIO THERAPEUTICS, INC. (CN) 2018-05-24 US disclosed
US-20160289668-A1 Production Method for Charged Non-Protein Amino Acid-Containing Peptide THE UNIVERSITY OF TOKYO (JP) 2016-10-06 US disclosed
EP-3031915-A1 PRODUCTION METHOD FOR CHARGED NON-PROTEIN AMINO ACID-CONTAINING PEPTIDE The University of Tokyo (JP) 2016-06-15 EP disclosed
EP-1834802-B1 Infrared-sensitive lithographic printing plate FUJIFILM CORP (JP) 2009-01-14 EP disclosed
EP-1834802-A1 Infrared-sensitive lithographic printing plate FUJIFILM Corporation (JP) 2007-09-19 EP disclosed
EP-0384636-A1 Pharmaceutically active compounds FISONS plc (GB) 1990-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200330501-A1 AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF APLNR, NPPA, ARGLU1 TSHR 315/4885CA12 4164/4885CA14 4400/4885
US-10351593-B2 Derivatives of dolastatin 10 and uses thereof PCSK9, DDOST, DHCR7 TSHR 4727/4885CA12 3795/4885CA14 2728/4885
US-20230124955-A1 AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF APLNR, NPPA, ARGLU1 TSHR 315/4885CA12 4164/4885CA14 4400/4885
US-20180141973-A1 Derivatives of Dolastatin 10 and Uses Thereof PCSK9, DDOST, DHCR7 TSHR 4727/4885CA12 3795/4885CA14 2728/4885
US-20190076462-A1 AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF APLNR, NPPA, ARGLU1 TSHR 315/4885CA12 4164/4885CA14 4400/4885
US-10682374-B2 Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof APLNR, NPPA, ARGLU1 TSHR 315/4885CA12 4164/4885CA14 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.